PharmiWeb.com - Global Pharma News & Resources
25-Apr-2023

Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results
Eckert & Ziegler Publishes Preliminary Figures for Q1/2023 with Double-digit Sales Growth, Earnings Decline and Confirmation of 2023 Full-Year Guidance

25-Apr-2023 / 17:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, April 25, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around 58 million EUR (previous year: 50) and a net profit of around 4.7 million EUR (previous year: 6.6) for the first quarter of 2023.

The significant increase in sales results from the renewed growth in demand for radioisotopes for pharmaceutical and industrial applications. This is offset by a lower gross margin due to a weaker product mix in the Isotope Products segment.

The main drivers of the decline in earnings compared to the previous year are however losses in the context of valuations of balance sheet items in foreign currencies and inflation adjustments in the hyperinflationary country of Argentina, which were not included in the first quarter of the previous year, totaling around EUR 1.5 million.

The forecast for fiscal year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under EUR 230 million and net income of around EUR 25 million.

The complete figures for the first quarter of 2023 will be published on May 11, 2023.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 



End of Inside Information

25-Apr-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1616873

 
End of Announcement EQS News Service

Editor Details

Last Updated: 25-Apr-2023